The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail

Lamzarin 30 mg prolonged-release tablets

Lexon Pharmaceuticals (Ireland) LimitedPA23176/004/001

Main Information

Trade NameLamzarin 30 mg prolonged-release tablets
Active SubstancesGliclazide
Dosage FormProlonged-release tablet
Licence HolderLexon Pharmaceuticals (Ireland) Limited
Licence NumberPA23176/004/001

Group Information

ATC CodeA10BB09 gliclazide


License statusAuthorised
Licence Issued05/04/2019
Legal statusProduct subject to prescription which may be renewed (B)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of Licence
Marketing StatusMarketed


Summary of Product CharacteristicsPDF Version
Package LeafletPDF Version
Public Assessment ReportPDF Version

Generics Information

Interchangeable List CodeIC0086-033-050
Interchangeable List DocumentPDF of Interchangeable List
« Back